valsartan has been researched along with Atheroma in 7 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 6 (85.71) | 24.3611 |
| 2020's | 1 (14.29) | 2.80 |
| Authors | Studies |
|---|---|
| Acanfora, C; Acanfora, D; Casucci, G; Ciccone, MM; Scicchitano, P | 1 |
| Liu, G; Wang, K; Zhang, H; Zhang, J; Zhang, W; Zhou, W | 1 |
| Černe, D; Drevenšek, G; Janić, M; Lunder, M; Marc, J; Šabovič, M; Zupan, J | 1 |
| Chai, M; Dong, Z; Ji, Q; Lin, Y; Liu, Y; Lu, Q; Meng, K; Wu, B; Yu, K; Zeng, Q; Zhang, J; Zhou, Y | 1 |
| Kang, Q; Li, P; Liu, H; Liu, W; Ma, C; Wang, N; Zhou, M | 1 |
| Chen, X; Deng, Y; Ding, D; Hu, X; Liao, Y; Pan, Y; Qiu, Z; Song, X; Wang, M; Wang, S; Wu, H; Yang, S; Zhang, H; Zhou, Y; Zhou, Z | 1 |
| Aono, J; Higaki, J; Horiuchi, M; Inoue, K; Iwai, M; Nagai, T; Nishimura, K; Ogimoto, A; Okayama, H; Suzuki, J | 1 |
7 other study(ies) available for valsartan and Atheroma
| Article | Year |
|---|---|
Neprilysin inhibitor-angiotensin II receptor blocker combination (sacubitril/valsartan): rationale for adoption in SARS-CoV-2 patients.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Animals; Apolipoproteins; Betacoronavirus; Biphenyl Compounds; Coronavirus Infections; COVID-19; Drug Combinations; Humans; Inflammation; Mice; Neprilysin; Pandemics; Plaque, Atherosclerotic; Pneumonia, Viral; SARS-CoV-2; Severe acute respiratory syndrome-related coronavirus; Tetrazoles; Valsartan | 2020 |
Neprilysin Inhibitor-Angiotensin II Receptor Blocker Combination Therapy (Sacubitril/valsartan) Suppresses Atherosclerotic Plaque Formation and Inhibits Inflammation in Apolipoprotein E- Deficient Mice.
Topics: Aminobutyrates; Angiotensin II Type 1 Receptor Blockers; Animals; Apolipoproteins E; Biphenyl Compounds; Chemokine CCL2; Drug Combinations; Drug Therapy, Combination; Gene Expression Regulation; Inflammation; Interleukin-6; Lipids; Matrix Metalloproteinase 8; Mice; Mice, Inbred C57BL; Mice, Knockout; Neprilysin; Plaque, Atherosclerotic; RAW 264.7 Cells; Tetrazoles; Valsartan | 2019 |
The low-dose atorvastatin and valsartan combination effectively protects the arterial wall from atherogenic diet-induced impairment in the guinea pig.
Topics: Animals; Aorta, Abdominal; Aorta, Thoracic; Atherosclerosis; Atorvastatin; Diet, Atherogenic; Drug Therapy, Combination; Female; Guinea Pigs; Heptanoic Acids; Interleukin-1beta; Male; Nitric Oxide Synthase Type III; Plaque, Atherosclerotic; Protective Agents; Pyrroles; Tetrazoles; Valine; Valsartan | 2014 |
Valsartan Attenuates Atherosclerosis via Upregulating the Th2 Immune Response in Prolonged Angiotensin II-Treated ApoE(-/-) Mice.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Antibodies, Monoclonal; Apolipoproteins E; Atherosclerosis; Blood Pressure; Body Weight; Disease Models, Animal; Inflammation; Interleukin-5; Lipids; Male; Mice; Mice, Knockout; Plaque, Atherosclerotic; T-Lymphocyte Subsets; Th2 Cells; Valsartan | 2015 |
Valsartan Promoting Atherosclerotic Plaque Stabilization by Upregulating Renalase: A Potential-Related Gene of Atherosclerosis.
Topics: Analysis of Variance; Angiotensin II Type 1 Receptor Blockers; Animals; Apolipoproteins E; Diet, High-Fat; Lipid Metabolism; Lipids; Male; Mice; Mice, Inbred C57BL; Monoamine Oxidase; Plaque, Atherosclerotic; Random Allocation; Real-Time Polymerase Chain Reaction; Valsartan | 2015 |
ATRQβ-001 vaccine prevents atherosclerosis in apolipoprotein E-null mice.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Antibodies, Neutralizing; Aorta; Apolipoproteins E; Apoptosis; Atherosclerosis; Chemokine CCL2; Coronary Vessels; Endothelial Cells; Humans; Macrophages; Male; Mice; Mice, Knockout; Plaque, Atherosclerotic; Receptor, Angiotensin, Type 1; Renin-Angiotensin System; Scavenger Receptors, Class E; Vaccines; Valsartan; Vasoconstrictor Agents | 2016 |
Deletion of the angiotensin II type 1a receptor prevents atherosclerotic plaque rupture in apolipoprotein E-/- mice.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Apolipoproteins E; Atherosclerosis; Carotid Artery Diseases; Carotid Artery, Common; CD36 Antigens; Disease Models, Animal; Disease Progression; Focal Adhesion Kinase 1; Gene Deletion; JNK Mitogen-Activated Protein Kinases; Lipids; Lipoproteins, LDL; Macrophages; Male; Matrix Metalloproteinase 9; Mice; Mice, Inbred C57BL; Mice, Knockout; NADPH Oxidases; Plaque, Atherosclerotic; Receptor, Angiotensin, Type 1; Rupture, Spontaneous; Superoxides; Tetrazoles; Time Factors; Valine; Valsartan | 2012 |